Lixisenatide
Lixisenatide (GLP-1 receptor agonist)
Also known as: Adlyxin, Lyxumia
An FDA-approved once-daily GLP-1 receptor agonist for type 2 diabetes, also studied for effects beyond glucose control.
Overview
Lixisenatide is a once-daily GLP-1 receptor agonist derived from exendin-4, approved for type 2 diabetes as Adlyxin. It particularly targets post-meal glucose through pronounced slowing of gastric emptying. Cardiovascular outcome data showed safety without a clear benefit. It is an established, approved member of the GLP-1 class.
Mechanism of action
Activates the GLP-1 receptor, enhancing glucose-dependent insulin release and markedly slowing gastric emptying to blunt post-meal glucose.
Key studies & citations
- Human2015
Lixisenatide in patients with type 2 diabetes and acute coronary syndrome (ELIXA)
6,068 patients: primary MACE hazard ratio 1.02, showing noninferiority to placebo but no cardiovascular benefit.
New England Journal of Medicine - Human2013
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin (GetGoal-L)
Placebo-corrected HbA1c reduction of 0.4% at 24 weeks with improved postprandial glucose and no weight gain.
Diabetes Care
Frequently asked questions
How is lixisenatide different from semaglutide?
Both are GLP-1 agonists, but lixisenatide is short-acting and dosed daily with a strong effect on post-meal glucose, while semaglutide is long-acting and produces greater weight loss.